We are dedicated to the pursuit of healthy skin to enhance self-confidence and a robust outlook for life.
Founded and funded by Paramount BioSciences with Robert Bitterman, Sr. and three former leaders from Dermik Laboratories (Aventis Pharma)
Selective development schedule for acquired molecules
Maruho acquisition consummated
Integrated Maruho North America Inc. into Cutanea
Cutanea Life Sciences, Inc. (CLS), an emerging U.S. prescription product development company, formally unveiled its new digital presence, www.cutanea.com, to the dermatology community in conjunction with this winter’s annual gathering of dermatologists from the U.S and around the world...
Multiple nationwide clinical research studies of an investigational gel for severe Rosacea are being conducted near you.
Cutanea Life Sciences, Inc. (CLS), an emerging U.S. prescription product development company...
Multiple nationwide clinical research studies of an investigational gel for severe Rosacea are being conducted near you.
Robert Bitterman founded Cutanea Life Sciences Inc. in September 2005 as its President, Chief Executive Officer, and Board Director. Mr. Bitterman has had an extensive and successful career in the pharmaceutical industry achieving various milestones, most notably, the sale of Cutanea to Maruho Company Ltd. in February 2012. Maruho is a privately owned Japanese dermatology-focused pharmaceutical company which celebrated its 100th year anniversary in October of 2015. During his tenure he has successfully transacted two proprietary technology license agreements in addition to acquiring a third technology and a commercially ready to market product. These form the foundation of Cutanea’s development and commercial operations for future value creation.
Mr. Bitterman also served as President and General Manager of Dermik Laboratories, the global dermatology strategic business unit of Aventis S.A. from 1994 into 2004. Under his direction Dermik secured FDA approval for six NDA’s (New Product Approvals) and one PMA, a class 3 medical device. He also directed eight commercial product launches in the U.S. and several product launches in other international markets. Mr. Bitterman was also responsible for constructing and directing an operating joint venture in the People’s Republic of China. During his ten year tenure at Dermik Laboratories he led his team in achieving average sales and EBITA growth of 21% and 24%, respectively. Prior to assuming senior operational leadership positions, Mr. Bitterman held various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman also held the position of President and Chief Executive Officer of Isolagen, Inc. from September 2004 until April 2005.
Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University. He also holds a Doctor of Human Letters (Honoris Causa) from the New York College of Podiatric Medicine and is a member of the Philadelphia Business Leaders Network.
He also serves as a director on the Board of Directors of Rxi Pharmaceutical Corporation.
Mr. Ferrara joined Cutanea Life Sciences, Inc. in December 2011 as its Chief Financial Officer. Mr. Ferrara has extensive experience in both publicly traded and venture capital/private equity backed, national and international companies in a variety of industries.
Previously, Mr. Ferrara was a Senior Financial Consultant with Rife & Associates, a management consulting firm that provides part-time CFO services and management consulting services to growing and expanding businesses. Additionally, Mr. Ferrara served as Chief Financial Officer of Storeroom Solutions Inc., and NER Data Products, Inc. as well as holding other senior financial positions with companies in the greater Philadelphia area. He is accomplished at thinking strategically and acting tactically with proven abilities in building and leading high performance, successful corporate finance organizations, HR and IT teams. His industry experience includes Life science (devices and biopharmaceutical companies); Environmental products & services; Technology enhanced logistics & supply chain services; and Manufacturing.
Mr. Ferrara is a CPA, having worked for PricewaterhouseCoopers, LLP, and a graduate of Lehigh University in Bethlehem, Pennsylvania.
Mr. Ferrara serves on the Board of Directors of DBI, Inc.; and on the Finance and Membership Committees of the Greater Philadelphia Senior Executive Group (GPSEG). Prior Board service includes the Board of Directors of the Planned Lifetime Assistance Network of PA., where he was on the Executive Committee and, Chairman of Governance and Audit Committees. He was previously the President of the Institute of Management Accountants (Delaware County Chapter).
Linda M. Mahoney has over 30 years of experience in both project leadership and product development across multiple dosage forms, including solid and liquid oral, inhalation, topical semi-solids, topical aerosols and sterile injectable products. Her contributions have led to numerous dermatological commercial product introductions. Ms. Mahoney joined Cutanea Life Sciences in March of 2012 as Vice President, Scientific Operations, a role she previously held with Cutanea from 2005-2008. Previously, she served as Sr. Director, Project Management & CMC at Quinnova Pharmaceuticals, Inc., in Newtown, PA. , Director of Project Management & Product Development at Isolagen Technologies, Inc. and Director, Project Management & Pharmaceutical Sciences at Dermik Laboratories, a division of Sanofi-Aventis.Ms. Mahoney received her B.A. in Chemistry from Lafayette College, Easton, PA. She is also a graduate of the Business Leadership Program associated with Aventis Pharma led by the Graduate School of Business, Columbia University.
Jennifer W. Phillips is a regulatory affairs professional having more than 20 years of experience in the pharmaceutical industry with 10 years in the dermatological drug development. Dr. Phillips has extensive background in development of regulatory strategy, to support new product registration and commercialization as well as review of promotional advertising materials for prescription drugs and medical devices. Dr. Phillips rejoined Cutanea Life Sciences as Vice President, Regulatory Affairs and Quality Assurance in April of 2012. She previously served as Sr. Director, Regulatory Affairs for CLS between 2005 and 2008. Prior to Cutanea, Dr. Phillips was Sr. Director, Regulatory Affairs for Mutual Pharmaceuticals Co. where she was primarily responsible for 505B2 development. In addition, Dr. Phillips also headed the Regulatory Affairs group for Dermik Laboratories, a division of Sanofi-Aventis. Dr. Phillips received her Doctor of Pharmacy from the University of North Carolina, Chapel Hill, NC. She supplemented her degree by completing a Clinical Research/Drug Development Fellowship from the University of North Carolina, Chapel Hill, NC. She received a Bachelor of Science-Pharmacy from the University of the Sciences, Philadelphia, PA. Dr. Phillips is also a graduate of the International Business leadership Program, University of Nijenrode, The Netherlands.
Gary L. Feiss is a clinical research expert with over 20 years of global experience in the research and development field, with emphasis in clinical research and regulatory affairs for drugs, diagnostics and medical devices. His therapeutic experience includes infectious disease, dermatology, respiratory, cardiovascular, neurology, vaccines, oncology, and surgical areas in drugs, in-vitro diagnostics, and companion diagnostics. Mr. Feiss joined Cutanea Life Sciences as Vice President, Clinical Operations in April of 2012. Prior to joining CLS, Mr. Feiss served as Vice President, Clinical Development and Regulatory Affairs at Saladax Biomedical, Inc., in Bethlehem, PA. In addition to this role, Mr. Feiss has worked in other clinical capacities, including, Director, Clinical Trials, at OraSure Technologies, Inc., Associate VP Head, Clinical Development and Regulatory Affairs at Dermik Laboratories, a division of Sanofi-Aventis, Vice President, Project Management and Regulatory Affairs at Covalent Group, Inc. Mr. Feiss received his Master of Science in Exercise and Sport Sciences from the University of Arizona, Tucson, AZ, as well as his Bachelor of Science in Health and Physical Education from Penn State University, University Park, PA.
Kazumasa Hirata’s resume includes more than 15 years of pharmaceutical industry experience specializing in dermatological drug development. Dr. Hirata began his career as a pharmacokinetics researcher, responsible for conducting ADME [Absorption, Distribution, Metabolism and Excretion] studies for drug candidate applications to PMDA [Pharmaceuticals and Medical Devices Agency], the chief regulatory authority in Japan. He has served as Project Manager in the United Kingdom, overseeing and managing drug development projects in the therapeutic categories of pruritus associated with atopic dermatitis, psoriasis, genital herpes and herpes zoster. Dr. Hirata joined Cutanea Life Sciences in February, 2016, as Vice President of Corporate development. He is a member of the CLS Board of Directors and as well as the President/CEO Leadership Team. As such, he is the primary liaison between CLS and its parent company, Maruho Co., Ltd. in Japan, responsible for facilitating operational communications between the two organizations. Dr. Hirata also serves as a member of the Portfolio Enrichment Committee, whose purpose is to identify potential new business opportunities which can advance the future development and growth of the company’s product portfolio.
Dr. Hirata obtained his Ph.D. from The School of Pharmacy, University of London (presently UCL School of Pharmacy). The title of his thesis was “Topical Formulation Strategies for a Model Acidic and a Model Basic Drug.”
Mr. Partridge brings marketing and communications experience spanning more than 20 years in the pharmaceutical industry to the CLS team. It marks the third major pharmaceutical effort headed up by Robert J. Bitterman, Sr., of which he’s been a part. He earned separate degrees in Business Administration/Marketing and International Politics, and has an extensive track record of successful messaging and positioning of brands and promotional campaigns both in and outside of U.S. markets. He has been a key member of launch and pre-launch teams for Sanofi-Aventis companies in the fields of oncology, hematology, and neurology prior to moving into dermatology in 1996. He led the launch of the first monoclonal antibody purified factor VIII replacement product, and worked on the pre-launch of Rhone-Poulenc Rorer’s lead chemotherapy product in the U.S., Taxotere. He also was part of the launch team for the first and only product approved by the FDA to treat amyotrophic lateral sclerosis, also known as Lou Gerhig’s Disease. His work also included a joint project with Dr. Jonas Salk’s ‘Immune Response Corporation’ which at the time was attempting to develop a successful vaccine for HIV. Within the dermatology specialty Mr. Partridge has experience with both medical and cosmetic product launches from a marketing and public relations perspective. He is currently the Chairman-Elect for the Board of Directors of the Greater West Chester (PA) Chamber of Commerce. He also sits on two other non-profit Boards in the Southeastern Pennsylvania region, for the Franklin Mint Federal Credit Union with assets over $1 billion, and the West Chester Area Education Foundation.
Lorrie Zimmerman joined Cutanea Life Sciences, Inc. in October 2013. She currently serves as Senior Manager, Human Resources. Previously Ms. Zimmerman was Executive Assistant to the President and CEO as well as Human Resources Representative. Ms. Zimmerman is currently responsible for employee recruitment, new hire on-boarding, training and development, expatriate assimilation and the development and implementation of Human Resources processes. In addition she manages payroll, benefits, and compliance with federal, state and local rules and regulations.
Ms. Zimmerman has over 20 years of experience in the global pharmaceutical industry which includes executive administration, finance and marketing services. She also spent seven years in direct sales and sales management in the retail industry.
Ms. Zimmerman has earned and received her certification in Human Resources Management through the University of Phoenix. She has been a member of the Society for Human Resources Management (SHRM) since January, 2014.
With more than 20 years of prescription pharmaceutical sales and sales management experience, Theresa Potenza’s successes have taken place in both the dermatology and professional eye care arenas.
Theresa joined Cutanea Life Sciences in January, 2016, as Director of Sales Strategy and Selling Operations. She worked directly with members of the current CLS Leadership Team while spending more than 15 years as part of Dermik Laboratories when it was a division of Sanofi-Aventis. She also worked with eye-care giant Bausch & Lomb for six years as a Regional Business Director in both the vision care and pharmaceutical divisions.
Theresa will be responsible for overall sales strategy and tactics through to execution. She is a graduate of Adelphia University, earning a BS in Marketing.
To create value by collectively applying our energies and expertise in the development of innovative technologies, optimizing intellectual property and therapeutic applications, culminating in market-leading products to treat diseases and disorders of the skin and subcutaneous tissue.
Six of the circles represent Cutanea's values of INTEGRITY, RESPECT, DISCIPLINE, RESILIENCE, INITIATIVE, and NETWORKING.
Three of the circles represent Maruho's values of INDIVIDUALS, EMPLOYEES, and MEMBERS OF SOCIETY.
Your Agreement and Consent
Definition of “Personal Information”
Information You Provide
Some areas of this Site may ask you to submit personal information in order for you to benefit from the specified features or to participate in a particular activity. When we collect personal information, we clearly label the information we are collecting. You have the sole and absolute discretion as to whether to provide personal information to us.
Passive Information Collection
Use and Disclosure of Information
We may use information collected through this Site to improve the content of the Site, to communicate with you, for our marketing and research purposes, and for any other purpose specified at the time the information is collected. In addition, we may use and disclose to others non-personal information collected through this Site without any restrictions.
No Third-Party Direct Marketing Use
Cutanea will not sell or otherwise transfer the personal information you provide us at this Site to any third parties for their own direct marketing use unless we have obtained your explicit consent for your data to be shared in this manner.
Personal Information Protection
We take measures designed to prevent unauthorized intrusion to this Site and the alteration, acquisition or misuse of personal information, however, we will not be responsible for loss, corruption or unauthorized acquisition or misuse of personal information that you provide through this Site or that is stored by us, or for any damages resulting from such loss, corruption or unauthorized acquisition or misuse.
This Site is not intended for children under the age of 18. We will not knowingly collect personal information through this Site from visitors in this age group. If you are a parent and you become aware that your child has provided us with information, please contact us as specified below, and we will work with you to address this issue.
Correction and Deletion of Personal Information
To keep personal information that you provide through this Site accurate, current and complete, please contact us as specified below and we will take appropriate steps to update or correct such information in our possession, or to delete your personal information from our contact list.
How to Contact Us
Cutanea Life Sciences, Inc.
1500 Liberty Ridge Drive
Wayne, PA 19087
Attention: General Counsel
www.Cutanea.com. User Agreement
THIS SITE AND THE CONTENT AND ANY EMAIL ALERT SERVICE AVAILABLE THROUGH THIS SITE ARE PROVIDED TO YOU ON AN “AS IS,” “AS AVAILABLE” BASIS WITHOUT WARRANTY OF ANY KIND, WHETHER EXPRESS OR IMPLIED, CREATED BY LAW, CONTRACT OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE, OR NON-INFRINGEMENT. CUTANEA MAKES NO REPRESENTATIONS OR WARRANTIES AS TO THE ACCURACY, COMPLETENESS, CURRENCY OR RELIABILITY OF THE CONTENT OR EMAIL ALERT SERVICE AVAILABLE THROUGH THIS SITE. YOU ARE RESPONSIBLE FOR VERIFYING ANY INFORMATION BEFORE RELYING ON IT. USE OF THIS SITE AND THE CONTENT AND EMAIL ALERT SERVICE AVAILABLE THROUGH THIS SITE IS AT YOUR SOLE RISK. CUTANEA MAKES NO REPRESENTATIONS OR WARRANTIES THAT USE OF THIS SITE OR THE EMAIL ALERT SERVICE WILL BE UNINTERRUPTED, ERROR-FREE OR SECURE. FURTHER, CUTANEA EXPRESSLY DISCLAIMS ANY OBLIGATION OR DUTY TO UPDATE OR CORRECT INFORMATION CONTAINED ON THIS SITE AND MAY CEASE THE EMAIL ALERT SERVICE AT ANY TIME, WITHOUT NOTICE TO YOU. YOU ARE RESPONSIBLE FOR TAKING ALL NECESSARY PRECAUTIONS TO ENSURE THAT ANY CONTENT OR MATERIAL YOU OBTAIN FROM THIS SITE OR THE EMAIL ALERT SERVICE IS FREE OF COMPUTER VIRUSES OR OTHER HARMFUL COMPONENTS.
Medical information that appears on this Site is for informational purposes only and is not, nor is intended to be, a medical diagnosis or a replacement for advice given by a physician or other medical professional. The information provided on this Site should not be relied upon as the basis of any health-care decision.
Links to Other Websites
This Site may link you to other websites that are not owned or controlled by Cutanea. The fact that we provide a link to a third party website does not mean that we endorse, authorize or sponsor that website. It also does not mean that we are affiliated with the third party website’s owners or sponsors. These links are provided for your convenience only. Cutanea expressly disclaims any responsibility for the content, the accuracy of the information, the quality of products or services provided by or advertised on these third-party sites and /or the collection and use of personally identifiable information by these third-party sites. If you choose to hyperlink to another website, You do so at your own risk. We reserve the right to terminate a link to a third party website at any time.
Links from Other Websites to this Site
If a third party links to this Site, it is not necessarily an indication of an endorsement, authorization, sponsorship, affiliation, joint venture or partnership by or with us. In most cases, we are not aware that a third party has linked to this Site. Cutanea expressly disclaims any responsibility for the content, the accuracy of the information, the quality of products or services provided by or advertised on these third-party sites and/or the collection and use of personally identifiable information by these third-party sites.
This Site contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained on this Site that are not historical facts are hereby identified as forward-looking statements for this purpose. Forward-looking statements generally can be identified by words such as “may,” “will,” “shall,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” and similar expressions , although not all forward-looking statements contain these identifying words. Forward-looking statements are based upon our current expectations and beliefs and are subject to risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries. In light of the significant uncertainties in forward-looking statements, you should not regard such statements as a representation or warranty that we will achieve our objectives and plans in any specified timeframe, and you should not place undue reliance on any forward-looking statements. While we may update certain forward-looking statements from time to time, we specifically disclaim any obligation to do so, whether as a result of new information, future developments or otherwise.
Intellectual Property Rights
All materials contained on this Site are protected by law, including but not limited to United States copyright and trademark law, as well as other state, national, and international laws and regulations. The contents of and all materials distributed in conjunction with this Site are Copyright © 2016 Dermarc, LLC, a wholly owned subsidiary of Cutanea Life Sciences, Inc., or its licensors, all rights reserved. Cutanea also owns a copyright in this Site as a collective work and/or compilation, and in the selection, coordination, arrangement, and enhancement of such content. The Cutanea name and logo, whether or not appearing with a trademark symbol, are trademarks of Dermarc, LLC, a wholly owned subsidiary of Cutanea Life Sciences, Inc. Unauthorized use of any material or trademarks contained on this Site may violate copyright laws, trademark laws, the laws of privacy and publicity, communications regulations and statutes and other laws and regulations. Please be aware that Cutanea actively and aggressively enforces its intellectual property rights to the fullest extent of the law. Copyright Owners’ Rights Under the Digital Millennium Copyright Act Of 1998 The Digital Millennium Copyright Act of 1998 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the internet infringes their rights under United States copyright law. If you believe in good faith that materials hosted by Cutanea infringe your copyright, you (or your agent) may send us a notice requesting that the materials be removed, or access to them blocked. If you believe in good faith that a notice of copyright infringement has been wrongly filed against you, the DMCA permits you to send us a counter-notice.
Notices and counter-notices must meet statutory requirements imposed by the DMCA. One place to find more information on the DMCA is the U.S. Copyright Office website. Notices and counter-notices for the Site should be sent to General Counsel, Cutanea Life Sciences, Inc., 1500 Liberty Ridge Drive, Suite 3000, Wayne, PA 19087.
Limitation of Liability
YOU ASSUME FULL RESPONSIBILITY AND ALL RISKS ARISING FROM ACCESS AND USE OF THIS SITE AND THE EMAIL ALERT SERVICE AVAILABLE THROUGH THIS SITE. IN NO EVENT SHALL CUTANEA OR ITS AFFILIATES, OR ANY OF THEIR RESPECTIVE OFFICERS, DIRECTORS, EMPLOYEES, SHAREHOLDERS, AGENTS, REPRESENTATIVES, SERVICE PROVIDERS OR LICENSORS, OR THEIR RESPECTIVE SUCCESSORS AND ASSIGNS, BE LIABLE FOR ANY DAMAGES OF ANY KIND OR NATURE (WHETHER BASED IN CONTRACT, TORT, STRICT LIABILITY OR OTHERWISE), INCLUDING BUT NOT LIMITED TO DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL (INCLUDING LOSS OF PROFITS), PUNITIVE OR OTHER DAMAGES, ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE EXISTENCE, ACCESS OR USE OF THIS SITE OR THE EMAIL ALERT SERVICE, REGARDLESS OF WHETHER CUTANEA OR ANY OF THE OTHER ENTITIES OR PERSONS LISTED ABOVE HAS BEEN ADVISED AS TO THE POSSIBILITY OF SUCH DAMAGES.